Comparison
Bromantane vs TB-500
Side-by-side of Bromantane and TB-500. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
TB-500
TB-500 peptide, a 17-aa thymosin beta-4 fragment. Preclinical tendon and wound healing via actin sequestration. Typical dosage 2 to 5 mg weekly. No human RCTs.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
TB-500
- •17-amino-acid fragment of endogenous Thymosin Beta-4, an actin-sequestering peptide
- •Preclinical models show accelerated tendon, ligament, and dermal wound healing
- •Equine veterinary use for soft-tissue injury is the most documented real-world application
- •Anecdotal human protocols use 2 to 5 mg twice weekly subcutaneously for 4 to 6 weeks
- •WADA banned under S2 (peptide hormones, growth factors) since 2018
- •No completed phase II or III human RCTs as of 2026; long-term safety unestablished
Side-by-side
| Attribute | Bromantane | TB-500 |
|---|---|---|
| Category | nootropic | peptide |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | Thymosin Beta-4 fragment, TB4-Frag, Thymosin Beta 4 |
| Half-life (hr) ↗ | 11 | 2 |
| Typical dose (mg) ↗ | 75 | 2.5 |
| Dosing frequency | daily, morning | 2x weekly (anecdotal protocols) |
| Routes | oral | subcutaneous, intramuscular |
| Onset (hr) | 3 | - |
| Peak (hr) | 168 | - |
| Molecular weight | 280.21 | 4963.4 |
| Molecular formula | C16H20BrN | C212H350N56O78S |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Sequesters G-actin monomers, modulates cell migration and angiogenesis, and upregulates VEGF and myosin transcription. Promotes endothelial differentiation and stem-cell migration to injury sites in preclinical models. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | Not FDA approved; research-use-only grey market; banned by WADA |
| WADA status | banned | banned |
| DEA / Rx | Not scheduled in the US | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Not recommended | Insufficient data |
| CAS | 87913-26-6 | 885340-08-9 |
| PubChem CID | 9576456 | 62707662 |
| Wikidata | Q4093816 | Q7799921 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
TB-500
Common side effects
- injection-site irritation
- fatigue (anecdotal)
- lethargy in early dosing (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established human safety profile
Interactions
- BPC-157: Frequently co-administered in anecdotal healing protocols; no controlled interaction data(minor)
Which Should You Take?
Bromantane comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-C outcome catalogued. TB-500 is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is post-training recovery, pick TB-500.
- → If your priority is tendon repair, pick TB-500.
Edge case: If you cannot self-administer injections, Bromantane is the only oral option in this pair.
Default choice: Bromantane. Wider use case, and broader goal coverage. Reach for TB-500 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and TB-500?
Bromantane and TB-500 differ in category (nootropic vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or TB-500?
Bromantane half-life is 11 hours; TB-500 half-life is 2 hours.
Can you stack Bromantane with TB-500?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper